Your browser doesn't support javascript.
loading
Comparative Effectiveness of Dynamic Treatment Strategies for Medication Use and Dosage: Emulating a Target Trial Using Observational Data.
Birnie, Kate; Tomson, Charles; Caskey, Fergus J; Ben-Shlomo, Yoav; Nitsch, Dorothea; Casula, Anna; Murray, Eleanor J; Sterne, Jonathan A C.
Afiliación
  • Birnie K; From the Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Tomson C; Department of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
  • Caskey FJ; From the Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Ben-Shlomo Y; Department of Renal Medicine, North Bristol NHS Trust, Bristol, United Kingdom.
  • Nitsch D; From the Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Casula A; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Murray EJ; Department of Nephrology, Royal Free London NHS Foundation Trust, London, United Kingdom.
  • Sterne JAC; UK Renal Registry, UK Kidney Association, Bristol, United Kingdom.
Epidemiology ; 34(6): 879-887, 2023 11 01.
Article en En | MEDLINE | ID: mdl-37757876
BACKGROUND: Availability of detailed data from electronic health records (EHRs) has increased the potential to examine the comparative effectiveness of dynamic treatment strategies using observational data. Inverse probability (IP) weighting of dynamic marginal structural models can control for time-varying confounders. However, IP weights for continuous treatments may be sensitive to model choice. METHODS: We describe a target trial comparing strategies for treating anemia with darbepoetin in hemodialysis patients using EHR data from the UK Renal Registry 2004 to 2016. Patients received a specified dose (microgram/week) or did not receive darbepoetin. We compared 4 methods for modeling time-varying treatment: (A) logistic regression for zero dose, standard linear regression for log dose; (B) logistic regression for zero dose, heteroscedastic linear regression for log dose; (C) logistic regression for zero dose, heteroscedastic linear regression for log dose, multinomial regression for patients who recently received very low or high doses; and (D) ordinal logistic regression. RESULTS: For this dataset, method (C) was the only approach that provided a robust estimate of the mortality hazard ratio (HR), with less-extreme weights in a fully weighted analysis and no substantial change of the HR point estimate after weight truncation. After truncating IP weights at the 95th percentile, estimates were similar across the methods. CONCLUSIONS: EHR data can be used to emulate target trials estimating the comparative effectiveness of dynamic strategies adjusting treatment to evolving patient characteristics. However, model checking, monitoring of large weights, and adaptation of model strategies to account for these is essential if an aspect of treatment is continuous.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anemia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Epidemiology Asunto de la revista: EPIDEMIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anemia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Epidemiology Asunto de la revista: EPIDEMIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido